Novartis and Zhejiang Tianyuan - Top 5 Emerging Markets Deals

Who: Novartis
Zhejiang Tianyuan
Where: China

Deal Size: $125 million

Details: In November 2009 Novartis forked over $125 million for 85 percent of Chinese vaccines maker Zhejiang Tianyuan. But that investment is just the tip of the iceberg. Novartis' then-CEO Daniel Vasella announced his intentions to make China the company's third largest market with a $1.25 billion investment in the country. (Vasella has since been replaced by Joe Jiminez).

Tianyuan is a privately-owned vaccine company with a range of marketed and experimental products focused on preventable viral and bacterial diseases. The vaccinemaker has seen its sales grow sharply since 2006 to $25 million in 2008. Novartis said it would invest in expanding Tianyuan's vaccine pipeline, manufacturing technologies and commercial networks.

Novartis and Zhejiang Tianyuan - Top 5 Emerging Markets Deals

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.